Beyond the vascular endothelial growth factor axis: update on role of imaging in nonantiangiogenic molecular targeted therapies in oncology.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 25905926.
- Also identified by DOI 10.2214/AJR.14.12876.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This article provides a comprehensive review of molecular targeted therapies that do not act directly through vascular endothelial growth factor pathways, highlighting the role of imaging in assessment of treatment response and drug toxicities. A substantial number of molecular targeted therapies act on nonantiangiogenic pathways. Familiarity with these drugs, their personalized tumor response criteria, and class- and drug-specific toxicities will help radiologists to be an integral part of the multi-disciplinary oncology team.
Medical subject headings
- Angiogenesis Inhibitors
- Antineoplastic Agents
- Diagnostic Imaging
- Molecular Targeted Therapy
- Neoplasms
- Protein Kinase Inhibitors